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Abstract
There is more need in the pharmacotherapeutical treatment, particularly in psychopharmacotherapy, to take into account 
the psychological factors that influence the effectiveness or ineffectiveness of treatment. It’s important to takes into 
account the holistic approach to the patient and a “brain-mind” concept is also inevitable in this approach.
Inefficiency of pharmacotherapy, treatment-resistence, non-adherence, nocebo etc. are only some of the phenomena 
that require a psychodynamic approach and the kind of creativity in prescribing drugs.
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How to deal with 
psychopharmacotherapeutic inefficiency
Jak radzić sobie z nieskutecznością psychofarmakoterapii
Introduction
For a long time we have faced with problems of ineffi-
ciency of drugs in many psychiatric patients. We are faced 
with many problems of treatment-resistence, non-adher-
ence, nocebo phenomena, intense side effects, etc. These 
conditions frustrate us as psychiatrists as well as patients 
themselves. In the understanding of these problems can 
help us psychodynamic psychopharmacotherapy that 
represents a compromising approach between biological 
psychiatry (and psychopharmacotherapy) and psycho-
dynamic psychotherapy. This approach includes many 
of the psychoanalytic and psychodynamic concepts, 
techniques, theories and therapeutical skills. 
Operating from either a dogmatic psychotherapeutic 
paradigm or a psychopharmacological paradigm means 
to denial patient in his holystic intergity. Transference 
issues and patient’s personality structure really have 
a greater impact on the selection, dosage, tolerability, 
and treatment outcome than is generally admitted.
How to deal with treatment resistance
 Neuroscientific researches prove that “biological” 
and  “psychological” constructs are impossible to di-
sentangle, and according to that it is useful to accept 
concept called “brain-mind”, rejecting anachronic dycho-
tomy such as “mental” vs.”physical”, “mind”vs.”body”, 
“psyche” vs. “soma”, etc. Accepting the application of 
“brain-mind” concept [1] offers explanation for many 
dilemmas, particularly for treatment resistance or non-
-adherence. Treatment resistance still remains as a serious 
psychiatric problem. Dynamic factors in psychopharma-
cology in that way play an important role in pharmaco-
logical treatment responsiveness. Psychodynamic psycho 
pharmacotherapy offers rational prescribing identifying 
irrational interferences with effective use of medications, 
and in that way trying to avoid the problems of the 
pharmacological treatment resistance. 
Psychodynamic psychopharmacology addresses the 
central role of meaning  and interpersonal factors in 
pharmacological treatment [2]. This approach includes 
postulates of psychoanalysis (the unconscious, conflict, 
resistance, transference, defense)  as powerful factors 
in successful pharmacotherapeutical treatment and 
are concordant with it. However, in treatment resistant 
patients, it is likely that psychodynamic factors (usually 
unconscious) are not in the line with therapeutic aims. 
But we must also admit that with the aim of treatment 
optimization, certain phenotypic genetic biomarkers 
undoubtedly play an important role in the recognition 
of treatment-responsive and unresponsive patients, and 
they reduce the risk of drug toxicity by enabling individual 
dosage adjustment. Therapeutic drug monitoring and 
pharmacogenetic testing both may improve acute and 
www.psychiatria.viamedica.pl86
Psychiatria 2015, tom 12, nr 2
long-term treatment, prediction of therapeutic respon-
se, possible correlations with treatment outcome, and 
monitoring of treatment compliance and can represent 
a prominent step towards creative psychopharmacothe-
rapy. However, despite ample evidence to the efficacy of 
these individualized procedures, they are still met with 
insurmountable financial and educational obstacles [3]. 
Psychodynamic psychopharmacotherapy helps prescri-
bers know how to prescribe pharmacy to improve outco-
mes, representing in a way an integration of biological 
psychiatry and psychodynamic insights and techniques. 
That fact can be simply illustrated by placebo phe-
nomena, which produces real, clinically significant, 
and  objectively measurable improvement. Producing 
measurable changes in brain activity placebo overlaps 
medication-induced improvements [4]. 
From a psychodynamic point of view, pharmacological-
-treatment resistance has different underlying dynamics 
and requires different kinds of interventions. Patients may 
be resistant to medication or resistant from medication. 
The first ones, resistant to medications, have conscious or 
unconscious factors that interfere with the desired effect 
of medications. It takes form of non-adherence but also 
in nocebo response. In contrast, resistant from medications 
are eager to receive the medication (or some benefit that 
the patient attributes to the medication) and although it 
may seems to relieve symptoms, there is no improvement 
in the patient’s quality of life. Resistance to medications and 
resistance from medications are not mutually exclusive, and 
many patients present both dynamics. 
The resistance phenomena are first described by Freud 
in 1905. when he discovered that many patients were 
unconsciously reluctant to relinquish their symptoms or 
were driven, for transference reasons, to resist the doctor. 
The same dynamics may apply in pharmacotherapy and 
may manifest as treatment resistance. When symptoms 
constitute an important defense mechanism, patients 
are likely to resist  medication effects until they have 
developed more mature defenses or more effective ways 
of coping. Defense mechanisms play important role in 
dynamics of resistance and vice versa [5]. 
Treatment-resistant patients do not function better with 
pharmacotherapy; on the contrary, some of them get 
worse. There are countless ways these medications may 
serve countertherapeutic and/or defensive aims. 
Mintz and Belnup [2] explored the phenomenon of 
treatment resistance in relation to medications. Actually 
they proposed and defined a discipline of “psychodyna-
mic psychopharmacology,” described its philosophical 
underpinnings and offered technical recommendations 
for the psychodynamic treatment of pharmacologic tre-
atment resistance. They suggest that many patients are 
“treatment-resistant” because patient’s psychodynamics 
is not incorporated into an understanding of repeated 
treatment failures. They also propose that psychodyna-
mic psychopharmacology advances the overall clinical 
effectiveness of medications in treatment-resistant pa-
tients by integrating a psychodynamic appreciation of 
the patient with a psychopharmacologic understanding. 
The proposition of a new discipline, psychodynamic psy-
chopharmacology, by D. Mintz and B. Belnap, offers not 
only a new discipline but also practical recommendations 
for the psychodynamic treatment of pharmacologic 
treatment resistance [6]. 
There are six principles for psychodynamic pharmaco-
logical practice with treatment-resistant patients [7]: 
1.  A psychodynamic psychopharmacotherapist comple-
tely refuses mind-body dualism, of course. Feelings, 
ideas, experiences,  relationships... all that change 
the structure and function of the brain, just as the 
state of the brain influences experience. Mind-body 
integration also means that psychotherapy and psy-
chopharmacology will need to be well-integrated so 
that psychopharmacological interventions facilitate 
the  psychotherapy and so that the therapy helps 
the  patient become conscious of psychological 
sources of pharmacological-treatment resistance. 
2. The central tenet of  psychodynamic psychophar-
macology is like somebody said: “It is much more 
important to know what sort of patient has a disease, 
than to know what sort of disease a patient has.” This 
practically means that the pharmacotherapist should 
get patient’s  developmental and social history to 
make reasonable hypotheses about the psychological 
origins of the patient’s treatment resistance. 
3. It is important to identify potential sources of ambi-
valence about symptoms, such as secondary gains, 
and communicative or defensive value of symptoms. 
It may be helpful at the point of intake to ask the 
patient what he would stand to lose  if treatment 
was successful.
4.  Negative transferences must be identified and wor-
ked through. Once potential sources of resistance to 
the medication or the doctor are understood, these 
must be addressed. If they are clear at the outset, 
they must be addressed preemptively. In this way, 
an alliance is made with the patient before massive 
resistance is sparked.  Empathic interpretation of 
nocebo responses can resolve adverse effects [7]. 
5. Countertherapeutic uses of medications should also 
be interpreted. A prescriber sometimes might be to-
lerable to the patient’s irrational use of medications, 
understanding that the patient is working through 
an issue that interferes with a healthier use of those 
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medications. In that way, psychopharmacotherapist 
can expect a condition of continued pharmacological 
treatment instead of countertherapeutic uses. 
6.  A medication regimen often reflects countertransfe-
rential  experience of the psychopharmacothera-
pist and such a regimen is unlikely to be effective. 
Sometimes is perhaps aimed at treating the doctor’s 
anxiety rather than the patient’s; the patient is not 
the only source of treatment resistance. A psychody-
namic psychopharmacotherapist must recognize his 
countertransferential problems in order to manage 
irrational prescribing. 
Prescribing medication, psychopharmacotherapist  al-
ways has to obtain the so called „psychotherapeutic fra-
me“ [8]. That frame is containing psychotherapy, within 
certain place and times and under certain condition, i.e. 
psychotherapeutic setting. 
Psychoanalytically speaking, on the part of the patient, 
frame comes to represent the 
most primitive part of the personality — it is the fusion of 
the ego-body-world on whose immobility depends the 
existence. Especially psychotic patients bring, in the 
most obvious way, their own frame into their the-
rapy,  and the therapist is the one who must enable 
to develop  it into a stabilizing foundation on which 
the  organization of the personality can take place. 
The psychotherapeutic frame is a permanent presence 
for the patient, and is comparable with the Winnicott’s 
concept of “holding” [9]. 
Placebo and therapeutic alliance 
Examples of the placebo effects can be found in every 
field of medicine. Mechanism of action of this pheno-
menon is yet unknown although researches focused on 
the expectation model, the model of conditioned reflexes 
and the opioid model which are probably complemen-
tary. Lots of researches in this field show that thoughts 
and beliefs can have important influence on the human 
neurobiology and create therapeutic process in that way. 
It is important to continuously develop consciousness, 
especially through educational processes during the 
medical education, about the importance of placebo 
and nocebo phenomenon and then in clinical practise 
to keep in mind not to send messages that lower the 
patient’s hope. Psychiatry is the field of medicine where 
placebo and nocebo effects are mostly expressed and in 
concordance with that researched the most, especially 
in the treatment of depression, although placebo effect 
is impressive even in some studies on patients with 
schizophrenia [10]. 
The patient’s desire to change and his positive transfe-
rence can mobilize profound self-healing capacities. Re-
adiness to change is powerful determinant of treatment 
effectiveness, sometimes more potent than the type of 
the therapy [11].
There is a large placebo-controlled, multicenter trial 
of  treatment of depression that showed that patient 
were  most likely to respond when they received the 
active drug but had a strong therapeutic alliance, which 
in its essence contents positive transference phenomena. 
Patients who received placebo and had a  strong the-
rapeutic alliance had a significantly better therapeutic 
response than patient who received an antidepressant 
but had a poor therapeutic alliance [12]. 
While positive transference often lead to positive 
responses, negative transference are  likely to lead to 
negative responses, to nocebo responses [13]. Many 
of them who experience intolerable adverse effects to 
medication are nocebo responders, and many of them 
become treatment-resistant. 
Psychodynamic approach and attachment
Psychodynamic psychopharmacotherapy  and “brain-
-mind” concept can be observed in the frame of transdi-
sciplinary holistic integrative psychiatry, that is approach 
“...built on the premise that human beings in health and 
disease are complex systems of dynamically interacting 
biological, psychological, social, energetic, informational 
and spiritual processes” [14]. 
And psychodynamic  psychopharmacotherapy in that 
mean accepts the application of “brain-mind” concept 
resolving many dilemmas, putting at the stake questions 
of compliances, nonadherences, placebo, nocebo, thera-
peutic alliance, treatment resistance, etc. [15]. 
Psychodynamic theory is a framework that could be helpful 
in clarifying our understanding of non-adherence. In par-
ticular, looking at the contributions of attachment theory 
and research has allowed us to deepen our understanding 
of non-adherence. Strengthening the therapeutic alliance 
and  fostering collaborative physician-patient relation-
ships may result in improved adherence [16]. Cohen and 
his colleagues in 2001. have written about the connection 
between early childhood trauma and non-adherence or 
resistance in adult  patients with posttraumatic stress 
disorder and comorbid depression. They postulated that 
traumatized patients’  sense of a foreshortened future 
may be related to failure to engage in or accept medical 
treatment, which suggests that early childhood trauma is 
a psychological risk factor for adult non-adherence [17]. 
Psychotherapeutic interventions based on at-
tachment  theory could help patients who are nonad-
herent to  treatment by stressing the importance of 
collaborative relationships, relinquishing excessive self-
-reliance and control, and promoting trust. Each modality 
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of treatment, either psychotherapy or pharmacotherapy, 
or their synergistic combination, may be effective in the 
light of “brain-mind” concept. Applying that concept in 
the frame of psychodynamic psychopharmacotherapy re-
solves many previous dilemmas, and particularly questions 
of compliances or non-adherences, placebo or nocebo, 
therapeutic alliance or treatment resistance, etc. Empathy 
and attachment are those to address the problems of non-
-adherence. There is a lack of information concerned with 
the psychological aspect of prescribing medications. This 
is striking since many patients require both treatments. 
As prescribers, our lack of empathy often stems from an 
unconscious need to feel isolated from our patients, to 
defend ourselves against overwhelming 
distress and maintain emotional  distance. A collabo-
rative stance promotes adherence,  while paternalistic 
or categorical medication advice could be perceived as 
coercive and could result  in non-adherence. A  recent 
focus on the interface between attachment theory and 
psychoanalytical theory has deepened our understanding 
of the psychodynamics of non-adherence. 
Attachment theory is based on the premise that early 
life  experiences with caregivers (mother, parents, or 
their substitute) are internalized and determine how in-
dividuals relate to others in adulthood [18]. Attachment 
concepts were originally conceived to understand the 
evolutionary, adaptive, and biological aspects of parent-
-infant care giving. Most recently, clinical research has 
validated the usefulness of  attachment concepts in 
understanding non- adherence [19]. 
The disruption in attachment bonds can lead to proble-
matic behavior during childhood and possibly across the 
life span. Research has demonstrated that the caregiver’s 
sensitivity to the infant’s needs is essential to ensure 
secure  attachments.  Adults with secure attachment 
experienced  consistently responsive caregiving parents, 
while adults with dismissing attachment had avoidant 
parents who were consistently emotionally unresponsive. 
Adults with secure attachment are comfortable depending 
on others and are readily comforted by them. Adults 
with dismissing style become compulsively self-reliant, 
describe  themselves as independent and self-sufficient, 
and are uncomfortable being close to or trusting of others. 
Awareness of dismissing attachment behaviors in our 
nonadherent patients can help us reframe our  psy-
chotherapeutic work. Wallin describes the  process of 
therapeutic interventions with dismissing individuals as 
“moving from isolation to intimacy.” In the early stages 
of treatment, he encourages a keen awareness of subtle 
affective cues and nonverbal  communication,  to help 
patients be comfortable in letting others in and in being 
treatment collaborators [20]. 
A collaborative approach must be based on a mutual re-
spect, trust, and openness that, along with an awareness 
of typical transference and countertransference issues, can 
increase the likelihood of a positive treatment outcome [21].
Psychodynamic psychopharmacology creates opportuni-
ties for a richer and more effective understanding of the 
entire therapeutic process, in which pharmacotherapy is 
applied in the treatment of mental disorders. It is a way of 
thinking about the pharmacotherapy of mental illness that 
incorporates both pharmacological and psychodynamic 
knowledge in a practical clinical approach and treatment-
-related decision making [22]. It is also very important to 
integrate psychodynamics and neuroscientific data becau-
se of similar patterns that exist in them. Many neuroscien-
tific discoveries have just reaffirmed the psychodynamic 
postulates (just to mention concept of “attachment” and 
the role of the limbic brain). Medical psychoanalysts, who 
comprehend dynamic and brain mechanisms should find 
an increasing theoretical and practical convergence of 
their work. The dynamic psychiatrist actively participates 
in the resolution of a given symptom picture and fosters 
improvement of the patient’s personality structure to 
maximize functioning [23].
In every illness, both mind and body can be affected to 
different extents. It is difficult to discern which manife-
stations of an illness are rooted in the body and which in 
the mind. Evidence shows that psychotherapy influences 
the biology of the brain, and that pharmacotherapy 
influences the psychological, social and developmental 
dimensions of the individual as well as their overall 
functioning and well-being. Every practicing physician, 
regardless of their medical discipline, uses in their eve-
ryday practice both biological and psychological appro-
aches to help successfully treat the patient [24]. Each 
set of interventions influences cerebral electro-chemical 
processes and each takes place within an evolving the-
rapeutic relationship which proceeds through different 
stages. One of the major challenges to current clinical 
psychiatry is the development of firm guidelines for 
combined therapy [25].
In contemporary psychiatry, a psychodynamic perspective 
must be preserved because without it, both diagnostic 
understanding and treatment planning will suffer [26].
Conclusion
This viewpoint considers the phenomena that inhibit 
or hinder psychopharmaceutical efficiency: treatment 
resistence, nocebo, non-adherence, transferential and 
therapeutic alliance problems and many others. 
It is underlined the importance of psychodynamic 
psychopharmacotherapy and holistic approach to the 
patient.
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Streszczenie
W leczeniu farmakologicznym, a zwłaszcza psychofarmakologicznym, powinny być w większym stopniu uwzględnia-
ne czynniki psychologiczne, które wpływają na skuteczność lub brak skuteczności leczenia. Ważne jest wzięcie pod 
uwagę konieczności całościowego podejścia do pacjenta, a w ramach takiego podejścia koncepcja wzajemnej relacji 
„mózgu−umysłu” jest czynnikiem, który nie może być pominięty. Brak skuteczności farmakoterapii, oporność wobec 
leczenia farmakologicznego, trudności w przestrzeganiu zaleceń, efekt nocebo to jedynie kilka przykładów zjawisk, któ-
rych zrozumienie i poradzenie sobie z nimi wymagają podejścia psychodynamicznego i pewnego rodzaju kreatywności  
w sposobie stosowania farmakoterapii. 
Autorka proponuje zastosowanie zasad i metod psychodynamicznej psychofarmakoterapii w celu rozwiazywania prob-
lemów w trakcie prowadzenia terapii lekami psychotropowymi, a także uwzględnienie zjawisk opisywanych przez teorię 
przywiązania w kontekście poprawy współpracy w leczeniu, stosowania się do zaleceń oraz w celu tworzenia wzajemnej 
relacji terapeutycznej w ramach poprawy skuteczności farmakoterapii.
Psychiatria 2015; 12, 2: 85–89
słowa kluczowe: brak skuteczności farmakoterapii, podejście psychodynamiczne, całościowe  
podejście do pacjenta
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10. Požgain I., Požgain Z., Degmečić D. Placebo and nocebo effect: 
a mini-review. Psychiatr. Danub. 2014: 100−107.
11. Beitman B.D., Beck N.C., Deuser W.E. et al. Patient stage of change 
predicts outcome in a panic disorder medication trial. Anxiety 
1994; 1: 64−69. 
12. Krupnick J.L. The role of therapeutic alliance in psychotherapy and 
pharmacotherapy outcome: findings in the National Institute of 
Mental Health Treatment of Depression Collaborative Research 
Program. J. Consult. Clin. Psychol. 1996; 64: 532−539. 
13. Hahn R.A. The nocebo phenomenon: scope and foundations. In: 
Harrington A. (ed.)
14. The placebo effect: an interdisciplinary exploration. Harvard Uni-
versity Press, Cambridge, MA, 1997. 
15. Jakovljević M. Transdisciplinary holistic integrative psychiatry — 
a wishful thinking or reality? Psychiatr. Danub. 2008; 20: 341−348. 
16. Vlastelica M. Effects of meaning or psychodynamic psycopharma-
cotherapy. Psychiatr. Danub. 2010; 22: 313−316. 
17. Alfonso CA: Understanding the psychodynamics of nonadherence. 
Psychiatric Times 2011; available at www.psychiatrictimes.com/
display/article/
18. Cohen M.A. The impact of PTSD on treatment adherence in persons 
with HIV infection. Gen. Hosp. Psychiatry 2001; 23: 294−296. 
19. Bowlby J. Attachment and loss. Vol. 1. Basic Books, New York, 1969. 
20. Ciechanowski P.S., Katon W.J., Russo J.E., Walker E.A. The patient-
-provider relationship: attachment theory and adherence to treat-
ment in diabetes. Am. J. Psychiatry 2001; 158: 29−35. 
21. Wallin D.J. Attachment in Psychotherapy. Guilford Press, New York, 2007. 
22. Bush F.N., Gould E. Treatment by a psychotherapist and a psychop-
harmacologist: transference and countertransference issues. Hosp. 
Community Psychiatry 1993; 44: 772−774.
23. Murawiec S. Psychodynamic psychopharmacology in clinical practice 
– interpretations of the adverse impact of pharmacotherapy. Arch. 
Psychiat. Psychother. 2009; 4: 51−56. 
24. Olarte S.W. The dynamic psychiatrist: internist of the mind. J. Am. 
Acad. Psychoanal. Dyn. Psychiatry 2009; 37: 287−289.
25. Groeleger U. Pharmacotherapy for the soul and psychotherapy for 
the body. Psychiatr. Danub. 2007; 19: 206−208.
26. Beirman B.D. Pharmacotherapy as an intervention during the stages 
of psychotherapy. Am. J. Psychother. 1981; 35: 206−214.
27. Gabbard G.O. Psychodynamic psychiatry in the “decade of the 
brain”. Am. J. Psychiatry 1992; 149: 991−998.
